These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 28301425

  • 1. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
    McAllister JW, Towns JM, Mcnulty A, Pierce AB, Foster R, Richardson R, Carr A.
    AIDS; 2017 Jun 01; 31(9):1291-1295. PubMed ID: 28301425
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY, ARIA study team.
    Lancet HIV; 2017 Dec 01; 4(12):e536-e546. PubMed ID: 28729158
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.
    Valin N, Fonquernie L, Daguenel A, Campa P, Anthony T, Guiguet M, Girard PM, Meyohas MC.
    BMC Infect Dis; 2016 Nov 29; 16(1):718. PubMed ID: 27894270
    [Abstract] [Full Text] [Related]

  • 8. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
    Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell JM, García F, STRIBPEP Study Group.
    J Antimicrob Chemother; 2017 Oct 01; 72(10):2857-2861. PubMed ID: 29091217
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.
    Malinverni S, Bédoret F, Bartiaux M, Gilles C, De Wit S, Libois A.
    Sex Transm Infect; 2021 Aug 01; 97(5):329-333. PubMed ID: 33106437
    [Abstract] [Full Text] [Related]

  • 14. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X, Nwokolo N, Korologou-Linden R, Hill A, Whitlock G, Day-Weber I, McClure MO, Boffito M.
    HIV Med; 2018 Jan 01; 19(1):1-6. PubMed ID: 28657199
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team.
    Clin Infect Dis; 2017 Feb 01; 64(3):317-325. PubMed ID: 28013265
    [Abstract] [Full Text] [Related]

  • 17. Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis.
    Van Slyke L, Scott M.
    J Int Assoc Provid AIDS Care; 2018 Feb 01; 17():2325958218760846. PubMed ID: 29534653
    [Abstract] [Full Text] [Related]

  • 18. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
    Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY.
    J Acquir Immune Defic Syndr; 2018 Feb 01; 77(2):193-198. PubMed ID: 28991887
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
    Asif S, Baxevanidi E, Hill A, Venter WDF, Fairlie L, Masenya M, Serenata C, Sokhela S, Chandiwana N.
    AIDS; 2021 Dec 15; 35(Suppl 2):S117-S125. PubMed ID: 34261099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.